4’-甲氧基联苯-4-硼酸 | 156642-03-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4’-甲氧基联苯-4-硼酸
• 中文别名: 4'-甲氧基联苯基-4-硼酸；4'-甲氧基联苯-4-基硼酸
• 英文名称: 4'-methoxy-biphenyl-4-boronic acid
• 英文别名: (4'-methoxybiphenyl-4-yl)boronic acid；(4'-methoxy-[1,1'-biphenyl]-4-yl)boronic acid；[4-(4-methoxyphenyl)phenyl]boronic acid
• CAS: 156642-03-4
• 化学式: C₁₃H₁₃BO₃
• mdl: MFCD04039030
• 分子量: 228.055
• InChiKey: VIHQQLWZRRVBNE-UHFFFAOYSA-N

物化性质

• 熔点：
  209-211
• 沸点：
  418.6±55.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.07
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4’-Methoxybiphenyl-4-ylboronic acid
Product Name:
Synonyms: 4-(4-Methoxyphenyl)phenylboronic acid; 4’-Methoxybiphenyl-4-boronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4’-Methoxybiphenyl-4-ylboronic acid
Ingredient name:
CAS number: 156642-03-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C13H13BO3
Molecular weight: 228.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4’-甲氧基联苯-4-硼酸 在 palladium diacetate 、 正丁基锂 、 溴 、 potassium acetate 、 三溴化硼 、 potassium carbonate 、 一水合肼 、 二乙二醇 作用下， 以 四氢呋喃 、 二氯甲烷 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 28.67h， 生成 [4'-(2-Benzyl-benzo[b]thiophen-3-yl)-3-bromo-biphenyl-4-yloxy]-acetic acid methyl ester
  参考文献：
  名称：

  新型苯并呋喃和苯并噻吩联苯作为具有抗高血糖特性的蛋白酪氨酸磷酸酶1B的抑制剂。

  摘要：

  肝和外周组织中的胰岛素抵抗以及胰腺细胞缺陷是2型糖尿病的常见病因。现在已经认识到，胰岛素抵抗可以由胰岛素受体信号系统中在胰岛素与其受体结合后的位点的缺陷引起。蛋白酪氨酸磷酸酶（PTPases）已被证明是胰岛素受体的负调节剂。抑制PTPases可能是治疗2型糖尿病的有效方法。我们已经确定了两个新颖的苯并呋喃/苯并噻吩联苯氧代乙酸和磺酰水杨酸系列作为具有良好口服降血糖活性的有效PTP1B抑制剂。为了帮助设计这些抑制剂，晶体学研究试图鉴定酶抑制剂的相互作用。晶体配合物的拆分表明抑制剂与酶的活性位点结合，并通过在两个疏水口袋中形成的氢键和范德华相互作用而保持在适当的位置。在含氧乙酸系列中，苯并呋喃/苯并噻吩联苯骨架第2位的疏水取代基与催化位点的Phe182相互作用，对分子的内在活性至关重要。催化位点口袋的疏水区被氧代乙酸部分的α-碳或邻位芳族位置的疏水取代基所利用和利用。水杨酸型抑制剂上类似的邻位

  DOI：

  10.1021/jm990560c
• 作为产物：
  描述：

  4-乙酰氧基-4'-溴代联苯 在 sodium hydroxide 、 正丁基锂 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 水 为溶剂， 反应 6.0h， 生成 4’-甲氧基联苯-4-硼酸
  参考文献：
  名称：

  The Synthesis and Property of Liquid Crystalline 4-Alkoxyl-4″-Cyano-p-Terphenyls

  摘要：

  The synthesis of some new 4-alkoxyl-4 "-cyano-p-terphenyls is described. The preliminary characterization by means of polarized optical microscopy, differential scanning calorimetry and X-ray diffraction shows that all these compounds are thermotropically liquid-crystalline and can form both the nematic and smectic mesophases.

  DOI：

  10.1080/10587250008031039

文献信息

• [EN] POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES<br/>[FR] COMPOSÉS POLYCYCLIQUES ET MÉTHODES POUR LA DÉGRADATION CIBLÉE DE POLYPEPTIDES DU FIBROSARCOME RAPIDEMENT ACCÉLÉRÉ
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2020051564A1

  公开（公告）日：2020-03-12

  The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物ULM—L—PTM，其作为快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及含有一端结合到相应E3泛素连接酶的Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，另一端结合到目标蛋白RAF的部分，使得目标蛋白与泛素连接酶靠近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白的聚集或积累，或目标蛋白的构成性激活导致的疾病或紊乱。
• p-Nitroterphenyl units for near-infrared two-photon uncaging of calcium ions
  作者：Thuy Thi Thu Pham、Satish Jakkampudi、Ko Furukawa、Fung-Yu Cheng、Tzu-Chau Lin、Yoki Nakamura、Norimitsu Morioka、Manabu Abe

  DOI：10.1016/j.jphotochem.2021.113154

  日期：2021.3

  (83 % for 1a, 45 % for 1b) from commercially available starting materials. One- and two-photon photochemical excitations of the synthesized terphenyl derivatives featuring two different electron-donating groups (dimethylamino (NMe2) and methoxyl (OMe)), which were thermally stable at least 36 h at 37 C in HEPES buffer (pH 7.4), were conducted to clarify the substituent effect on the photophysical and

  近红外双光子（NIR-2P）解笼反应可用于精确研究生物活性化合物在各种现象中的作用。在这项研究中，我们合成了具有三联苯骨架的新型NIR-2P响应发色团，其特征在于乙二醇四乙酸（EGTA）单元作为Ca 2+选择性螯合剂。对光不稳定的Ca 2+螯合剂以高产率（83％对合成1a中，为45％1B从市售的起始原料）。具有两个不同的供电子基团（二甲氨基（NMe 2）的合成三联苯衍生物的单光子和双光子光化学激发）和甲氧基（OMe））在HEPES缓冲液（pH 7.4）中在37°C时至少热稳定36 h，以阐明取代基对光物理和光化学性质的影响。所述NME 2基团，其是较强的供电子基团，导致了更高的双光子截面（σ 2 = 75 GM在780nm处）相比，OME组（σ 2在720nm处= 9 GM）在pH = 7.4 HEPES缓冲溶液中，尽管NMe 2取代的一个的摩尔消光系数（ε）（在λmax = 363 nm处的ε
• Imidazo[1,2-<i>c</i> ]pyrimidin-5(6<i>H</i> )-one as a novel core of cyclin-dependent kinase 2 inhibitors: Synthesis, activity measurement, docking, and quantum mechanical scoring
  作者：Haresh Ajani、Josef Jansa、Cemal Köprülüoğlu、Pavel Hobza、Vladimír Kryštof、Antonín Lyčka、Martin Lepsik

  DOI：10.1002/jmr.2720

  日期：2018.9

  We report on the synthesis, activity testing, docking, and quantum mechanical scoring of novel imidazo[1,2‐c]pyrimidin‐5(6H)‐one scaffold for cyclin‐dependent kinase 2 (CDK2) inhibition. A series of 26 compounds substituted with aromatic moieties at position 8 has been tested in in vitro enzyme assays and shown to inhibit CDK2. 2D structure‐activity relationships have ascertained that small substituents

  我们报告了新型咪唑并[1,2 - c ]嘧啶-5（6 H）-1支架对细胞周期蛋白依赖性激酶2（CDK2）抑制的合成，活性测试，对接和量子力学评分。在体外酶法中已经测试了一系列在位置8处被芳香族部分取代的26种化合物，并显示出抑制CDK2的作用。二维结构与活性的关系已确定，位置8处的小取代基（最大为萘基或甲氧基苯基的大小）通常会导致单位数微摩尔IC 50较大的取代基（取代的联苯）会降低化合物的活性。使用Glide对接获得的化合物的结合模式在CDK2上显示出最多2个铰链区氢键，并且在抑制剂核心的取向和8个取代基的位置上有所不同。基于半经验量子力学的计分方法确定了可能的有利结合模式，这将有助于未来基于结构的设计以及杂环核取代基的合成优化。总之，我们已经确定了CDK2抑制的新核心，并将进一步探索以增加化合物的效力并监测其对其他蛋白激酶的选择性。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20180179183A1

  公开（公告）日：2018-06-28

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；目标蛋白）的调节剂而发挥作用。具体而言，本公开涉及含有一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，该配体与相应的E3泛素连接酶结合，并且另一端含有结合目标蛋白RAF的基团，使得目标蛋白与泛素连接酶靠近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白的聚集或积累，或目标蛋白的构成性激活导致的疾病或紊乱。
• Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
  申请人：American Home Products Corporation

  公开号：US06232322B1

  公开（公告）日：2001-05-15

  This invention provides compounds of Formula I having the structure wherein A, R3, R4, and R5 are as defined hereinbefore in the specification, or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

  这项发明提供了具有结构的化合物，其中A、R3、R4和R5如前述说明中所定义，或其药学上可接受的盐，这些化合物在治疗与胰岛素抵抗或高血糖相关的代谢紊乱方面是有用的。